CDK4 and neoplasm: Moreover, Teo and colleagues have shown, that the CDK4/6 inhibitor ribociclib does not impair activation and cytotoxic potential of tumor-infiltrating CD8+ and CD4+ T cells in a triple-negative breast cancer mouse model (Teo et al., 2017).